DOES BLOCKING PROINFLAMMATORY CYTOKINES DIMINISH CANCER-RELATED FATIGUE?

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS The primary goal of this study is to experimentally probe the association between proinflammatory cytokines and fatigue using a cytokine antagonist, infliximab (Remicade). Infliximab is FDA approved for treatment of rheumatoid arthritis and other inflammatory conditions and has been shown to reduce proinflammatory cytokines and behavioral disturbances in these patients. This Phase II pilot study will evaluate the feasibility of administering infliximab to breast cancer survivors with persistent fatigue and determine the effects of infliximab on proinflammatory cytokines, fatigue, and other behavioral symptoms.